BioMed X

What BioMed X does

BioMed X is a privately held biomedical innovation hub founded in 2013 in Heidelberg, Germany, that operates at the interface between academia and the pharmaceutical industry. The company's core operating model combines crowdsourcing, design thinking, and structured boot camp selection to identify top early-career academic researchers worldwide and embed them in 4-5 year collaborative research projects. Sourcing runs through the proprietary BioMed X Career Space platform, which holds over 15,000 registered researchers, and is supplemented by 41 crowdsourcing calls and 42 boot camps executed since inception. BioMed X has created 35 research and startup teams and completed 19 research projects, with 74% of project IP acquired by partners.

The business serves two primary customer verticals: pharmaceutical companies (AbbVie, Novo Nordisk, Merck KGaA, Roche, Sanofi, Boehringer Ingelheim, Servier, Janssen, Daiichi Sankyo, Ono Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer) and global health foundations (Bill & Melinda Gates Foundation). Revenue is generated through professional services-style industry partnerships and grant-funded research, with no publicly disclosed pricing. The company operates five locations (Heidelberg and New Haven research institutes, Ridgefield and Paris-Saclay startup incubators branded as XSeed Labs, and the XFem Labs women's health accelerator) and runs multiple programs including XBridge (industry-academic collaborations with Harvard) and the AION Labs joint venture for AI-driven antibody engineering.

The product portfolio combines physical research infrastructure with proprietary technology platforms. Notable technology assets include the BioMedAgent multi-agent LLM framework for autonomous biomedical data analysis, the T-FINDER Platform for T cell response analysis against cancer vaccines, and a T Cell Immunology Discovery Platform for cognate epitope mapping. Research spans oncology, immunology, platform technologies, and artificial intelligence, with active use cases in oral peptide formulation (Novo Nordisk, GLP-1 receptor agonists), neuroscience/anhedonia (AbbVie), AI-driven antibody engineering (Servier), multispecific biologics for cancer (Daiichi Sankyo), and AI-enabled modeling of diabetic kidney disease (Government of Barbados). Legal entity is BioMed X AG, a German Aktiengesellschaft, headquartered at Im Neuenheimer Feld 515, 69120 Heidelberg, with 11-50 employees.

Name

BioMed X

Legal name

BioMed X AG

Website

https://bmedx.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

BioMed X is a Heidelberg-based biomedical innovation hub founded in 2013 that runs 4-5 year collaborative research projects with global pharmaceutical companies (AbbVie, Novo Nordisk, Roche, Merck KGaA, Sanofi, Boehringer Ingelheim, and others) and foundations like the Gates Foundation, using crowdsourcing and a 15,000+ researcher Career Space platform to assemble project teams.

Ownership category

akta.pro rank

Product category

Contract Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Biomedical research services
• Drug discovery outsourcing
• Pharmaceutical R&D
• Biomedical innovation hub
• Crowdsourced research

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Industry Partnerships: BioMed X partners with pharma companies to conduct exploratory research on challenges identified by industry partners. Results and IP from research projects are transferred to pharmaceutical partners after completion.
2. Foundation Grants: Supported by grants from foundations such as the Gates Foundation for specific research initiatives like women's health programs

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

BioMed X operates a network of biomedical research institutes, startup incubators, and R&D accelerators that deliver sponsored exploratory research for pharmaceutical partners and global health funders. It identifies therapeutic and platform R&D challenges from industry partners, crowdsources global academic talent through its Career Space platform and boot camp selection process, embeds recruited research teams within its institutes in Heidelberg, New Haven, Paris-Saclay, and Ridgefield, and transfers the resulting research outputs and IP back to sponsors after 4-5 year project terms.

Product overview

BioMed X is a biomedical innovation hub that operates multiple research institutes (Heidelberg, New Haven), startup incubators (XSeed Labs in Ridgefield and Paris-Saclay), and specialized accelerators (XFem Labs for women's health). The company combines crowdsourcing with incubation, partnering with pharmaceutical companies to identify key challenges across therapeutic areas and recruit top academic talent to co-create solutions. Core offerings include the BioMed X Institute facilities, XSeed Labs startup incubators, XBridge industry-academic collaboration platform, the BioMedAgent AI framework for autonomous biomedical data analysis, and the T-FINDER Platform for T cell response analysis. Since 2013, they have created 35 research/startup teams, completed 19 projects, and performed 41 crowdsourcing calls.

Differentiator

Problem solved

Functional benefit

Brands

• XFem Labs: Women's health R&D accelerator launched in Heidelberg, Germany, with focus on non-hormonal contraceptives for low- and middle-income countries.
• XSeed Labs
• XBridge
• AION Labs

Products and services

• BioMed X Institute Heidelberg Biomedical research institute located in Heidelberg, Germany (Im Neuenheimer Feld 515, 69120 Heidelberg) that conducts crowdsourced, industry-partnered research projects across therapeutic areas and transfers results and IP to pharmaceutical partners after 4-5 year project terms.
• BioMed X Institute New Haven U.S.-based BioMed X research institute in New Haven, CT, hosting industry-partnered research teams including the AbbVie collaboration in immunology and tissue engineering that began in 2023.
• XSeed Labs Ridgefield Venture-creating incubator in Ridgefield, USA, operated in partnership with Boehringer Ingelheim to support biomedical startups and early-stage innovation teams emerging from BioMed X research.
• XSeed Labs Paris-Saclay BioMed X venture-creating incubator at Servier's Paris-Saclay campus combining AI and immunology expertise to advance next-generation biologics through startup creation.
• XFem Labs Heidelberg Women's health R&D accelerator in Heidelberg, Germany, that develops targeted therapeutics and technologies for women's health, including non-hormonal contraceptives for women in low- and middle-income countries, funded by foundation grants and partnerships.
• XBridge Program Program to facilitate structured research collaborations between academic investigators and pharmaceutical industry scientists via sponsored research agreements, initially piloted with Harvard University.
• BioMedAgent Multi-agent LLM framework with self-evolving capabilities for autonomous, tool-aware biomedical data analyses, integrating multiple data types (text, structured data, multimodal) to perform biomedical research workflows.
• BioMed X Career Space Global talent-sourcing platform with 15,000+ registered researchers that supports the identification, application, and boot camp selection of early-career academic researchers for BioMed X research projects.

Quantifiable outcome

• 74% Research Project IP Acquired by Partners
• +3 more outcomes

Named customers15 records

Segments2 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature1 record

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

• Government of BarbadoscoreStrategic or Co-development Partner · 29 January 2026Partnership with the Government of Barbados and European Union's PharmaNext Programme for AI-enabled modeling of early diabetic kidney disease in the Barbadian population. Project includes deep molecular profiling and AI-driven modeling.
• Harvard UniversitymajorStrategic or Co-development Partner · 27 January 2026XBridge framework pilot initiative to facilitate structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements.
• AbbViecoreStrategic or Co-development Partner · 25 November 2025New neuroscience research collaboration in the USA focused on understanding anhedonia and identifying therapeutic targets. Project analyzes brain microcircuits and molecular mechanisms using interdisciplinary approaches.
• Novo NordiskcoreStrategic or Co-development Partner · 19 August 2025Collaboration to develop innovative oral peptide formulation technologies for GLP-1 receptor agonists. Research project titled 'Prolonged Retention of Oral Peptide Formulations in the Gut' aims to improve absorption and bioavailability.
• ServiercoreStrategic or Co-development PartnerLaunch of first research team in France (XSeed Labs Paris-Saclay) to pioneer AI-driven antibody engineering. Partnership brings together AI and immunology expertise to advance next-generation biologics.
• Boehringer IngelheimcoreStrategic or Co-development PartnerJoint XSeed Labs incubator in the U.S. expanded to support startup companies in biomedical innovation.
• Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development PartnerMultiple oncology and immunology research collaborations including extrachromosomal DNA in cancer research, with extensions of research programs over multiple years.
• RochemajorStrategic or Co-development PartnerResearch collaboration in the field of immunology and AI for drug development.
• SanofimajorStrategic or Co-development PartnerResearch collaboration on artificial intelligence for drug development.
• JanssenmajorStrategic or Co-development PartnerImmunology research collaboration with expansion of strategic collaboration over time.
• Daiichi SankyomajorStrategic or Co-development PartnerCollaboration for multispecific biologics in cancer therapy and new research team in immuno-oncology.
• Ono PharmaceuticalminorStrategic or Co-development PartnerNew collaboration in cancer research (immuno-oncology) at BioMed X Institute Heidelberg.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Large CRO providing outsourced drug discovery and preclinical services to pharma; broader portfolio but competes for the same outsourced exploratory R&D spend.
• IQVIA: Global life sciences services and clinical research organization; much broader but overlaps with BioMed X in pharma R&D outsourcing and informatics services.

Emerging players

• Recursion Pharmaceuticals: AI/ML-enabled drug discovery platform combining high-throughput biology with machine learning; competes for the same pharma partnership and licensing dollars as BioMed X's AI-led offerings.
• Wild Design (Wellcome Leap / Gates Foundation R&D): Foundation-backed biomedical research programs; comparable in using venture-style funding structures to drive translational science, and overlaps with BioMed X's XFem Labs Gates-funded work.
• Insitro: Machine learning-driven drug discovery company with major pharma partnerships (Bristol Myers Squibb, Eli Lilly); comparable in marrying AI, data, and pharma R&D collaborations.
• Exscientia: AI-driven small molecule discovery company with pharma collaborations (Sanofi, BMS, Roche); competes for AI-driven pharma R&D budgets alongside BioMed X.

Others

• Mila (Quebec AI Institute): Academic-industry AI research institute partnering with pharma; adjacent because of similar academia-industry bridge model and AI-focused research output, though not a commercial CRO.

Direct peers

• AION Labs: AI-driven drug discovery hub jointly run by BioMed X and several pharma companies (AstraZeneca, Pfizer, Merck, Teva, AWS); directly comparable mission of crowdsourced biomedical innovation, and is explicitly noted as 'Powered by BioMed X'.
• AbCellera Biologics: Antibody discovery and engineering platform with deep pharma partnerships; directly comparable to BioMed X's antibody engineering work with Servier and others.
• LabCentral: Biotech startup incubator co-located with academic and pharma partners in Cambridge, MA; directly comparable mission of providing shared infrastructure and sponsorship pipelines for early-stage biomedical ventures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC_bFsCYwZ2FD3JhPk-IKkrA
• LinkedInlinkedin.com/company/biomed-x-gmbh
• Xx.com/BioMed_X
• Facebookfacebook.com/biomedx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMed X